Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTOKINETICS INC director John T. Henderson reported new equity awards. He received a grant of 2,851 shares of common stock at no cost, bringing his direct holdings to 78,088 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.1500 per share, exercisable starting on June 27, 2026 and expiring on May 26, 2036. In addition, 83 shares are reported as indirectly owned through his spouse. These are compensation-related awards, not open-market purchases or sales.
CYTOKINETICS INC director Edward M. Kaye, MD received new equity compensation. He was granted 2,851 shares of Common Stock and now directly holds 13,216 shares. He also received a non-qualified stock option for 4,301 shares at an exercise price of $77.15 per share, exercisable beginning on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics director B. Lynne Parshall received new equity awards. On 2026-05-27, she was granted 2,851 shares of Cytokinetics common stock at no cost, increasing her direct holdings to 20,784 shares.
She was also granted a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share, expiring on 2036-05-26. These awards are compensation-related grants rather than open-market purchases or sales.
CYTOKINETICS INC director Robert E. Landry reported equity grants. He received 2,851 shares of Common Stock at no cost, increasing his direct holdings to 10,184 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.15, exercisable starting on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards. On May 27, 2026, he received 2,851 shares of Common Stock as a grant at no cash cost, increasing his direct holdings to 35,488 shares.
He was also granted a Non-Qualified Stock Option for 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option is scheduled to become exercisable starting June 27, 2026 and expires on May 26, 2036, adding to his long-term incentive position with the company.
Cytokinetics director Nancy Wysenski received new equity awards in the form of common shares and stock options. She was granted 2,851 shares of Common Stock at no purchase price, increasing her directly held stake to 33,917 shares. She also received a Non-Qualified Stock Option covering 4,301 shares of Common Stock with an exercise price of $77.1500 per share, exercisable into the same number of underlying shares and expiring on May 26, 2036. These awards are classified as grants or awards rather than open-market purchases or sales.
Cytokinetics, Incorporated reported the results of its Annual Meeting of Stockholders held on May 27, 2026. Stockholder participation was high, with 116,125,730 shares represented, or 93.47% of the 124,237,822 shares entitled to vote, establishing a quorum.
Stockholders elected three Class I directors to three-year terms: Edward M. Kaye, M.D., Wendell Wierenga, Ph.D., and Nancy J. Wysenski. They also approved an amendment and restatement of the 2015 Employee Stock Purchase Plan to increase the authorized shares reserved for issuance under the plan by 1,000,000 shares of common stock.
Investors ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold shares in Cytokinetics Inc. On May 19, 2026, he exercised options for 3,500 shares of common stock at $7.80 per share and then executed an open-market sale of 3,500 shares at an average price of $75.69 per share. After these transactions, he directly holds 153,902 shares of common stock and 47,886 non-qualified stock options, indicating the sale represents a small portion of his overall equity position.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share. After this transaction, he directly holds 400,330 shares. Separate from his direct position, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Cytokinetics, Incorporated entered into an underwriting agreement for a public offering of 9,859,155 shares of its common stock at a public offering price of $71.00 per share.
The underwriters received a 30-day option to buy up to an additional 1,478,873 shares, which they fully exercised on May 7, 2026. After underwriting discounts, commissions and estimated expenses, net proceeds to Cytokinetics from the offering are approximately $760.2 million, providing substantial new capital to the company.